Literature DB >> 3390825

Flow cytometric analysis by bromodeoxyuridine/DNA assay of cell cycle perturbation of methotrexate-treated mouse L1210 leukemia cells.

M Tsurusawa1, M Niwa, N Katano, T Fujimoto.   

Abstract

The in vitro effects of methotrexate (MTX) on cell cycle progression and DNA synthesis of L1210 leukemia cells were studied by the bromodeoxyuridine (BrdUrd)/DNA analysis technique. Low dose (10(-8) M) MTX, which slightly inhibits clonal replication of the cells, delays progress across the S phase, and treatment for 24 h results in a slight increase of the S-phase population. Much higher doses (10(-7) M and 10(-6) M) of MTX, which strongly reduce the clonogenicity, prevented the progression of cells at the G1-S boundary and across the S phase, but not in the other phases. The cells arrested at the G1-S boundary were able to incorporate BrdUrd in the medium for 6-12 h after the start of treatment and then lost the ability to incorporate BrdUrd. By determining the colony inhibitory activity of MTX, it could be shown that not only S-phase cells but non-S-phase cells are susceptible to cytotoxicity of MTX. MTX-induced S-phase arrest is closely associated with an alteration in the distribution of BrdUrd-labeled cells, and MTX apparently inhibits BrdUrd incorporation into L1210 cells as the dose and duration of treatment increase. These results suggest that MTX-induced cell cycle perturbation is related to inhibition of DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390825

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

2.  Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Ramos; D Donato
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Activation markers and cell proliferation as indicators of toxicity: a flow cytometric approach.

Authors:  A Johannisson; A Thuvander; I L Gadhasson
Journal:  Cell Biol Toxicol       Date:  1995-12       Impact factor: 6.691

Review 4.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1995-12

5.  A study on the predictability of acute lymphoblastic leukaemia response to treatment using a hybrid oncosimulator.

Authors:  Eleftherios Ouzounoglou; Eleni Kolokotroni; Martin Stanulla; Georgios S Stamatakos
Journal:  Interface Focus       Date:  2017-12-15       Impact factor: 3.906

6.  A flow cytometric bromodeoxyuridine/DNA analysis for cytokinetics of the pancreatic cancer cell line Capan-2 after irradiation.

Authors:  B Nakata; Y S Chung; M Sowa
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

7.  The effect of NC-190, a novel antitumor compound, on the cell-cycle progression of HeLa S3 cells.

Authors:  T Yamagishi; S Nakaike; K Nanaumi; S Otomo; S Tsukagoshi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  The toxicity of organoarsenic-based warfare agents: in vitro and in vivo studies.

Authors:  J Henriksson; A Johannisson; P A Bergqvist; L Norrgren
Journal:  Arch Environ Contam Toxicol       Date:  1996-02       Impact factor: 2.804

9.  Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo.

Authors:  S W Blume; R C Snyder; R Ray; S Thomas; C A Koller; D M Miller
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

10.  Methotrexate cytotoxicity as related to irreversible S phase arrest in mouse L1210 leukemia cells.

Authors:  M Tsurusawa; M Niwa; N Katano; T Fujimoto
Journal:  Jpn J Cancer Res       Date:  1990-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.